Here are relevant reports on : infectious-disease-diagnostics-market
-
Middle East & Africa In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Infectious Disease) - Forecast to 2031
The Middle East & Africa in vitro diagnostics (IVD) market, valued at USD 3.33 billion in 2025, stood at USD 3.49 billion in 2026 and is projected to advance at a resilient CAGR of 4.8% from 2026 to 2031, culminating in a forecasted valuation of USD 4.42 billion by the end of the period.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration - Global Forecast to 2029
The global poultry medicine/pharmaceuticals market, valued at US$4.73 billion in 2023, stood at US$5.01 billion in 2024 and is projected to advance at a resilient CAGR of 5.9% from 2024 to 2029, culminating in a forecasted valuation of US$6.68 billion by the end of the period. The growth of the poultry medicine/pharmaceutical industry can be attributed to the rising global population and consumption of poultry meat and eggs leading to more poultry farming practiced notably in the developing regions where poultry is the cheapest source of protein.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Respiratory Care Device Market by Product (PAP Devices, Ventilators, Humidifiers, Oxygen Concentrators, Spirometers, Peak Flow Meter, Masks), Disease Indication (Asthma, Infectious Disease), & End User (Hospitals, ASCs) - Forecast to 2031
The Asia Pacific respiratory care devices market is projected to reach USD 8.76 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe Human Microbiome Market, valued at US$0.22 billion in 2024, stood at US$0.29 billion in 2025 and is projected to advance at a resilient CAGR of 28.6% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. The growth of the Europe human microbiome market is driven by increased awareness of personalized health, the adoption of microbiome-based therapies, and advancements in sequencing technologies and bioinformatics.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
US Respiratory Care Device Market by Product (PAP Devices, Ventilators, Humidifiers, Oxygen Concentrators, Spirometers, Peak Flow Meter, Masks), Disease Indication (Asthma, Infectious Disease), End User (Hospitals, Home Care Settings) - Forecast to 2031
The US Respiratory Care Devices market, valued at US$9.40 billion in 2025, stood at US$10.02 billion in 2026 and is projected to advance at a resilient CAGR of 7.8% from 2026 to 2031, culminating in a forecasted valuation of US$14.56 billion by the end of the period. This growth is primarily driven by an increasing prevalence of chronic respiratory diseases such as COPD, asthma, and sleep apnea, along with an aging population that is more susceptible to breathing disorders.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Europe Respiratory Care Device Market Product (PAP Devices, Ventilators, Humidifiers, Oxygen Concentrators, Spirometers, Peak Flow Meter, Masks), Disease Indication (Asthma, Infectious Disease), End User (Hospitals, Homecare Settings)- Regional Forecast to 2031
The europe respiratory care devices market, valued at USD 5.97 billion in 2025, stood at USD 6.33 billion in 2026 and is projected to advance at a resilient CAGR of 7.2% from 2026 to 2031, culminating in a forecasted valuation of USD 8.96 billion by the end of the period. The key players in the Europe respiratory care devices market are Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), ResMed Inc. (US), Fisher & Paykel Healthcare Limited (New Zealand), Drägerwerk AG & Co. KGaA (Germany), GE Healthcare (US), Masimo (US), and among other players.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Respiratory Care Devices Market by Product (PAP Devices, Ventilators, Humidifiers, Oxygen Concentrators, Spirometers, Peak Flow Meter, Masks), Disease Indication (Asthma, Infectious Disease), End User (Hospitals, Homecare Settings) - Global Forecast to 2030
The global respiratory care devices market, valued at US$22.2 billion in 2024, stood at US$23.6 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of US$33.6 billion by the end of the period. Various demographic, medical, and environmental factors propel market growth in respiratory care equipment. Among these is the increase in the global prevalence of respiratory conditions.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
North America Respiratory Care Device Market by Product (PAP Device, Ventilator, Humidifier, Oxygen Concentrator, Spirometer, Peak Flow Meter, Mask), Disease Indication (Asthma, Infectious Disease), End User (Hospital, Homecare Setting)-Forecast to 2031
The North America Respiratory Care Device market, valued at US$9.88 billion in 2025, stood at US$10.53 billion in 2026 and is projected to advance at a resilient CAGR of 7.8% from 2026 to 2031, culminating in a forecasted valuation of US$15.31 billion by the end of the period. The North America respiratory care devices market has been growing as the number of chronic respiratory diseases, such as COPD, asthma, and sleep apnea, continues to rise.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Manufacturing Services Market by Type (Fermentation & Downstream Processing, Strain Development & Optimization), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease) - Global Forecast to 2031
The global Human Microbiome Manufacturing Services market, valued at US$0.09 billion in 2024, stood at US$0.11 billion in 2025 and is projected to advance at a resilient CAGR of 16.7% from 2025 to 2031, culminating in a forecasted valuation of US$0.27 billion by the end of the period. Growing demand for specialized capabilities, such as anaerobic fermentation, microbial process scale-up, formulation, and fill-finish, is fueling broader adoption of human microbiome manufacturing services.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) – Global Forecast to 2026
The immunofluorescence assays market is expected to grow from USD 2.6 billion in 2021 to USD 83.5 billion by 2026, at a compound annual growth rate (CAGR) of 6.0% during the forecast period.Thermo Fisher Scientific Inc (US), Abcam PLC (UK), Bio-Rad Laboratories, Inc (US), PerkinElmer Inc. (US), Merck KGaA (Germany), Werfen Company (Spain), Cell Signaling Technology, Inc. (US), MEDIPAN GmbH (Germany)
- Published: February 2021
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50